Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

Trial Details

NCT ID
NCT04628026
Phase
PHASE3
Sponsor
University of Ulm
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Venetoclax
  • Placebo
  • Standard chemotherapy
  • Allogeneic stem cell transplantation
Locations (sample)
  • Innsbruck, Austria|47.26266,11.39454
  • Linz, Austria|48.30639,14.28611
  • Rankweil, Austria|47.27108,9.64308
  • Salzburg, Austria|47.79941,13.04399
  • Vienna, Austria|48.20849,16.37208

Key Eligibility Criteria

  • Patients with newly diagnosed acute myeloid leukemia (AML) according to the International Consensus Classification (ICC).
  • Age ≥ 18 and ≤ 75 years.
  • Patients considered eligible for intensive chemotherapy.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →